In recent trading session, Lyra Therapeutics Inc (NASDAQ:LYRA) saw 0.47 million shares changing hands at last check today with its beta currently measuring 0.02. Company’s recent per share price level of $0.29 trading at -$0.02 or -5.19% at last check today assigns it a market valuation of $17.92M. That most recent trading price of LYRA’s stock is at a discount of -2241.38% from its 52-week high price of $6.79 and is indicating a discount of -3.45% from its 52-week low price of $0.30. Taking a look at company’s average trading volume volume of 3.33 million if we extend that period to 3-months.
Lyra Therapeutics Inc (NASDAQ:LYRA) trade information
Upright in the red during last session for losing -5.19%, in the last five days LYRA remained trading in the red while hitting it’s week-highest on Monday, 06/10/24 when the stock touched $0.29 price level, adding 9.18% to its value on the day. Lyra Therapeutics Inc’s shares saw a change of -94.39% in year-to-date performance and have moved -8.24% in past 5-day. Lyra Therapeutics Inc (NASDAQ:LYRA) showed a performance of -17.37% in past 30-days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Lyra Therapeutics Inc (LYRA) estimates and forecasts
Statistics highlight that Lyra Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -92.56% of value to its shares in past 6 months, showing an annual growth rate of 4.07% while that of industry is 14.20. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 1.40% from the last financial year’s standing.
5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 350k for the same. And 5 analysts are in estimates of company making revenue of 350k in the next quarter. Company posted 458k and 370k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -21.63% during past 5 years. In 2024, company’s earnings growth rate is likely to be around -0.63% while estimates for its earnings growth in next 5 years are of -1.60%.
LYRA Dividends
Lyra Therapeutics Inc is more likely to be releasing its next quarterly report in July and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
